Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance
- PMID: 20034369
- DOI: 10.2174/157339910790909396
Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance
Abstract
Overweight and obesity is a growing "world-wide epidemic problem". Because as many as, two-thirds of the adult population and a growing number of children are overweight. The prevalence of diabetes, especially type 2 diabetes and hypertension have significantly increased with the prevalence of obesity. Obesity accompanying type 2 diabetes and hypertension are known to be closely linked with insulin resistance and elevated sympathetic nervous activity. It has been well documented that obesity, hypertension, and diabetes are high risk factors for subsequent cardiovascular and renal complications. Many patients are both diabetic and hypertensive, while they are obese, but not all diabetic patients have hypertension, indicating that insulin resistance is not only a mechanism for blood pressure elevation in diabetic-hypertensive patients. Several investigators have reported that sympathetic nervous activation relates to cardiovascular complications in patients with hypertension, diabetes, and obesity, and that sympathetic nerve activity accompanying insulin resistance is closely linked with left ventricular hypertrophy in healthy subjects. In addition, sympathetic nerve activation may predict future renal injury in healthy normotensive subjects. These findings suggest that elevated sympathetic nerve activity associated with insulin resistance may contribute to the onset and maintenance of cardiovascular and renal complications in diabetes, and hypertension in obesity. Further, genetic polymorphisms of the beta2- and beta3-adrenoceptor gene have been associated with type-2 diabetes and insulin resistance in many epidemiological studies and might be another factor responsible for the close relationship between insulin resistance and heightened sympathetic nerve activity. Thus, focusing on the interactions between insulin resistance, sympathetic nervous activity and beta-adrenoceptor polymorphisms might help in understanding the precise relationships between insulin resistance and sympathetic nerve activity in type 2 diabetes and obesity-related hypertension. The purpose of this article is to provide a synthesis of the current findings on the mechanisms of the onset and maintenance of cardiovascular and renal complications in obesity, diabetes and hypertension. A better understanding of the relationships of sympathetic nervous system activity and insulin resistance might help with the clinical treatment of diabetes and hypertension in obesity. Further, to clarify the pathogenesis and mechanisms of the association between obesity, diabetes, and hypertension may lead to reductions in cardiovascular and renal risk.
Similar articles
-
Sympathetic nervous system, diabetes, and hypertension.Clin Exp Hypertens. 2001 Jan-Feb;23(1-2):45-55. doi: 10.1081/ceh-100001196. Clin Exp Hypertens. 2001. PMID: 11270588 Review.
-
The role of sympathetic nervous activity in renal injury and end-stage renal disease.Hypertens Res. 2010 Jun;33(6):521-8. doi: 10.1038/hr.2010.35. Epub 2010 Mar 26. Hypertens Res. 2010. PMID: 20339374 Review.
-
Beta2-adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals.Am J Hypertens. 2005 Jul;18(7):1009-14. doi: 10.1016/j.amjhyper.2005.01.006. Am J Hypertens. 2005. PMID: 16054001
-
[Insulin resistance and arterial hypertension].Herz. 1995 Feb;20(1):16-32. Herz. 1995. PMID: 7713473 Review. German.
-
[Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension].Ann Ital Med Int. 1997 Oct-Dec;12(4):217-22. Ann Ital Med Int. 1997. PMID: 9773576 Review. Italian.
Cited by
-
Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.J Am Heart Assoc. 2012 Oct;1(5):e002279. doi: 10.1161/JAHA.112.002279. Epub 2012 Oct 25. J Am Heart Assoc. 2012. PMID: 23316290 Free PMC article. Clinical Trial.
-
Sarcolipin trumps β-adrenergic receptor signaling as the favored mechanism for muscle-based diet-induced thermogenesis.FASEB J. 2013 Sep;27(9):3871-8. doi: 10.1096/fj.13-230631. Epub 2013 Jun 10. FASEB J. 2013. PMID: 23752204 Free PMC article.
-
Adenosine kinase inhibition protects the kidney against streptozotocin-induced diabetes through anti-inflammatory and anti-oxidant mechanisms.Pharmacol Res. 2014 Jul;85:45-54. doi: 10.1016/j.phrs.2014.05.004. Epub 2014 May 17. Pharmacol Res. 2014. PMID: 24841126 Free PMC article.
-
Bilirubin Increases Insulin Sensitivity by Regulating Cholesterol Metabolism, Adipokines and PPARγ Levels.Sci Rep. 2015 May 28;5:9886. doi: 10.1038/srep09886. Sci Rep. 2015. PMID: 26017184 Free PMC article.
-
Synergistical action of the β2 adrenoceptor and fatty acid binding protein 2 polymorphisms on the loss of glomerular filtration rate in Chinese patients with type 2 diabetic nephropathy.Int Urol Nephrol. 2018 Apr;50(4):715-723. doi: 10.1007/s11255-018-1812-2. Epub 2018 Feb 5. Int Urol Nephrol. 2018. PMID: 29404926
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical